New treatment for age-related macular degeneration
Transformational next generation high affinity trispecific fab protein to address unmet needs in Ophthalmology
This study is testing a new protein treatment for age-related macular degeneration (AMD) that aims to help improve vision and reduce the need for frequent eye injections, making it easier for older adults to manage their condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revopsis Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Springfield, United States) |
| Project ID | NIH-11004408 on NIH RePORTER |
What this research studies
This research focuses on developing a next-generation protein treatment aimed at addressing the unmet needs in ophthalmology, specifically for age-related macular degeneration (AMD). AMD is a leading cause of vision loss in older adults, and the study aims to create a high-affinity trispecific fab protein that can effectively reduce the abnormal growth of blood vessels in the eye. By targeting key factors involved in retinal diseases, this approach seeks to improve patient outcomes and reduce the frequency of necessary eye injections. Patients may benefit from a more effective and less burdensome treatment option for AMD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of age-related macular degeneration.
Not a fit: Patients with non-age-related vision issues or those who do not have AMD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for age-related macular degeneration, potentially preserving vision for millions of patients.
How similar studies have performed: Previous research has shown promise in developing targeted therapies for retinal diseases, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Springfield, United States
- Revopsis Therapeutics, INC. — Springfield, United States (Active)
Researchers
- Principal investigator: Xu, Li — Revopsis Therapeutics, INC.
- Study coordinator: Xu, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.